Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295: How the GHRH Analog Works, and What Research Shows

CJC-1295: How the GHRH Analog Works, and What Research Shows CJC-1295: How the GHRH Analog Works, and What Research Shows CJC-1295 is one of the most referenced growth-hormone-releasing peptides in the research literature, and one of the most frequently confus

By Recovery & Performance Peptides Editorial Team

CJC-1295: How the GHRH Analog Works, and What Research Shows

CJC-1295: How the GHRH Analog Works, and What Research Shows

CJC-1295 is one of the most referenced growth-hormone-releasing peptides in the research literature, and one of the most frequently confused. Part of that confusion comes from two closely related versions of the molecule that get used interchangeably online but behave very differently. This overview walks through what CJC-1295 actually is, how it's understood to work, the DAC-versus-no-DAC distinction that trips people up, and how to evaluate a research-grade preparation.

This article is for educational and research reference only. It is not medical advice, and Element materials are sold for laboratory and research use.

What CJC-1295 is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). The body's own GHRH is a signaling peptide released by the hypothalamus that tells the pituitary gland to secrete growth hormone. It's a short-lived molecule by design — it acts in pulses and is broken down quickly.

CJC-1295 is built on the first 29 amino acids of GHRH — the fragment that carries the biological activity — with targeted amino-acid substitutions that protect it from the enzymes that normally degrade natural GHRH. The result is a GHRH-like molecule that resists breakdown far longer than the native hormone. That stability is the entire point of the modification, and it's the property most of the research interest is built on.

The DAC vs no-DAC distinction

This is the single most important thing to understand, because the two forms are often sold under the same "CJC-1295" name:

CJC-1295 with DAC carries a Drug Affinity Complex — a chemical group that lets the peptide bind reversibly to albumin, a protein that circulates in blood. Tethered to albumin, the molecule persists far longer, which in research settings translates to a substantially extended half-life measured in days rather than minutes.

CJC-1295 without DAC — more accurately called modified GRF (1-29) or "mod GRF 1-29" — keeps the stabilizing substitutions but omits the albumin-binding complex. It's still far more durable than natural GHRH, but its action is shorter and more pulse-like, closer to how endogenous GHRH behaves.

The distinction matters because the two forms produce different pharmacological profiles in study models: DAC creates a sustained elevation, while no-DAC produces a sharper, more transient signal. Researchers choose between them based on which profile a given experiment calls for. When you see "CJC-1295," always confirm which version a supplier is actually shipping — the certificate of analysis should specify it.

How it's understood to work

CJC-1295 acts on the GHRH receptor on pituitary cells. By mimicking GHRH but resisting degradation, it prolongs the signal that prompts the pituitary to release growth hormone. Downstream of growth hormone, the liver produces IGF-1 (insulin-like growth factor 1), the mediator through which many of GH's effects are studied.

A key concept in the research framing is that CJC-1295 works upstream, at the level of the body's own release machinery, rather than introducing growth hormone directly. In study models this preserves the pituitary's natural pulsatile pattern of secretion — one of the reasons GHRH analogs are of interest to researchers studying the GH axis as a system rather than just flooding it with exogenous hormone.

Why it's often paired with a GHRP in research

In the literature, GHRH analogs like CJC-1295 are frequently studied alongside a second class of peptides — growth-hormone-releasing peptides (GHRPs) such as ipamorelin. The rationale is mechanistic: GHRH analogs and GHRPs act on two different receptors and two different pathways that both converge on growth hormone release. Studied together, they've been reported to produce a combined effect greater than either alone, because they're pulling two separate levers on the same system.

This pairing is a recurring theme in GH-axis research, which is why the two peptides are so often discussed in the same breath. It's a mechanistic observation from study models, not a usage recommendation.

What the research has examined

Most of the relevant work sits in a few areas:

GH and IGF-1 dynamics. The core body of research looks at how GHRH analogs affect growth hormone secretion patterns and downstream IGF-1 levels in animal and clinical pharmacology models.

Half-life and pharmacokinetics. A significant share of the CJC-1295 literature is specifically about the DAC modification and how albumin binding extends the molecule's duration — the foundational work that made the peptide notable in the first place.

The GH axis as a regulatory system. Because CJC-1295 acts upstream, it's used as a tool for studying how the hypothalamic-pituitary axis regulates growth hormone, rather than only its end effects.

As always, the honest framing is that this is characterized pharmacology in research contexts. Claims that leap from "affects GH secretion in a study model" to specific real-world outcomes run ahead of what the data support.

Stability, storage, and handling

For a research-grade lyophilized peptide, standard handling principles apply:

Store the sealed, freeze-dried powder cold and away from light. Lyophilized peptide is dramatically more stable than peptide in solution.

Once in solution, refrigerate and treat stability as a matter of weeks, not months.

Avoid repeated freeze-thaw cycles, which degrade peptides.

Use appropriate diluents. Research handling typically uses bacteriostatic water as the diluent because its preservative supports a longer usable window than sterile water once a vial is opened.

Label and date solutions so batches don't get mixed up.

These are storage and stability considerations for lab material — not a use protocol.

How to evaluate quality

CJC-1295 is a peptide where quality varies wildly between suppliers, so this is where your attention pays off:

Which version is it? The COA should state clearly whether it's CJC-1295 with DAC or without DAC (mod GRF 1-29). If a listing doesn't specify, that's a red flag.

Third-party COA. A legitimate supplier provides a Certificate of Analysis from an independent lab, batch-specific, not an in-house claim.

Purity by HPLC, with a stated figure (commonly ≥98%).

Identity by mass spectrometry, confirming the correct molecular weight for the specific version.

If a supplier can't produce a current, batch-matched COA that names the DAC status, treat the product as unverified.

Frequently asked questions

What's the difference between CJC-1295 and mod GRF 1-29? "Mod GRF 1-29" is CJC-1295 without the DAC complex. Both are stabilized GHRH analogs; the DAC version lasts far longer by binding to albumin, while the no-DAC version acts in a shorter, more pulse-like way.

Why is CJC-1295 studied with ipamorelin? They act on different receptors that both lead to growth hormone release, so in research models the combination produces a larger effect than either peptide on its own.

Does CJC-1295 contain growth hormone? No. It's a GHRH analog that acts on the body's own pituitary release machinery — it works upstream, not by adding growth hormone directly.

What should I check before buying? A current, third-party COA that names the version (DAC vs no-DAC) and reports HPLC purity and mass-spec identity for the specific batch.

Element supplies research-grade materials for laboratory use. Nothing here is medical advice or a recommendation for human use. Browse related research peptides for compounds studied in the same context.

Hexarelin

TB-500

Epithalon

Ipamorelin

Tirzepatide

CJC-1295 DAC

PT-141

Semaglutide

Selank

BPC-157

Sermorelin

Melanotan 2

IGF LR3

Tesamorelin

AICAR

IGF-DES

GHRP 2

Albuterol

Tamoxifen

Letrozole

Clomiphene

Tadalafil

Clenbuterol

Anastrozole

Finasteride

Exemestane

Sildenafil

Yohimbine

Bacteriostatic Water Recent Posts Melanotan 2 (MT2): Mechanism, Research, and Safety Considerations Ipamorelin: The Selective GHRP, Explained Tesamorelin: The GHRH Analog Studied for Visceral Fat Sermorelin: The Original GHRH Analog, Explained CJC-1295: How the GHRH Analog Works, and What Research Shows

Already a customer? Sign In

Create Account

All products on this site are for Research, Development use only. Products are Not for Human consumption of any kind. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

ElementSarms is a chemical supplier. ElementSarms is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. ElementSarms is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.

Sarms

Stacks

Research Liquids

Albuterol 5MG/ML | 30ML with dropper

Anastrozole 1.5MG/ML | 30ML with dropper

Clomiphene 50MG/ML | 30ML with dropper

Finasteride 5MG/ML | 30ML with dropper

Letrozole 3.5 MG/ML | 30ML with dropper

LiquiCia 30MG/ML | 30ML with dropper

LiquiCia T50 50MG/ML | 30ML with dropper

LiquiClen 200MCG/ML | 30ML with dropper

Liquistane / Exemestane 25MG/ML | 30ML with dropper

LiquiTamo 20MG/ML | 30ML with dropper

LiquiVia 25MG/ML | 30 ML with dropper

T3 LIOTHYRONINE 200MCG/ML | 30ML with dropper

Toremifene Citrate 60MG/ML | 30ML with dropper

Yohimbine HCL 10MG/ML | 30ML with dropper

Research Peptides

Aicar 50MG

BPC-157 + TB-500 Blend 2mg ea/ 4MG

BPC-157 5MG

CJC-1295 + DAC 2MG

CJC-1295 | No DAC 2MG

Epithalon 10MG

Frag Premium 176-191 5MG

GHK-CU Copper Peptide 50MG

GHRP-2 5MG

GHRP-6 5MG

Hexarelin 5MG

IGF-1 DES 1MG

IGF-1 LR3 1MG

Ipamorelin 5MG

Melanotan 2 10MG

NAD+ 500MG

PT-141 / Bremelanotide 10MG

GLP-1/GIP/GCG (RT)

Selank 5MG

GLP1 (SM)

Sermorelin 5MG

TB-500 5MG

GIP/GLP-1 (TZ)

PDE5 Inhibitors

GLP-1

Diluents

Bacteriostatic Water 10ML

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

STORAGE

Reconstitution and Storage: Essential Steps for Researchers

Handling peptides correctly after they arrive is absolutely critical for maintaining their stability and efficacy. We've seen promising research derailed by improper reconstitution or storage, and it's a frustrating, preventable setback. For any CJC-1295 beginners guide, this section is indispensable. When you receive your lyophilized (freeze-dried) CJC-1295, it's a stable powder. However, once you reconstitute it, things change. Reconstitution typically involves mixing the peptide powder with a sterile diluent, most commonly Bacteriostatic Reconstitution Water (bac). It's crucial to use the correct amount of diluent to achieve your desired concentration, and to do so gently. We recommend slowly adding the water down the side of the vial, then allowing it to dissolve naturally without vigorous shaking, which can degrade the peptide structure. This approach (which we've refined over years) delivers real results. Once reconstituted, CJC-1295 becomes much more fragile. It must be stored refrigerated, typically at 2-8°C (36-46°F), and kept away from light. Freezing can sometimes extend its lifespan further, but repeated freeze-thaw cycles are generally detrimental. Our team advises researchers to reconstitute only what they need for a specific period and to discard any unused portions after a recommended timeframe, usually a few weeks to a month, depending on the specific peptide and storage conditions. This meticulous approach ensures the integrity of your research material, ma…
02

Question drills

Open a question for its connected answer.

01What If CJC-1295 Elevates My IGF-1 But I See No Joint Improvement?+

This outcome is plausible and aligns with the indirect mechanism: IGF-1 elevation proves the GH axis is responding, but whether that elevation translates to cartilage repair depends on baseline joint pathology, age, inflammatory burden, and mechanical loading. Younger subjects with acute injuries may respond better than older subjects with chronic degenerative disease. The 2014 GH meta-analysis found cartilage effects only in GH-deficient populations. Eugonadal adults with normal baseline GH may not benefit. If IGF-1 rises but symptoms persist, the peptide is working pharmacologically but the joint pathology may require multimodal intervention beyond GH modulation alone.

SOURCE / realpeptides.co ↗
02What If the Reconstituted Solution Develops Cloudiness or Particles After a Week in the Fridge?+

Stop using the vial immediately. Cloudiness indicates either bacterial contamination or peptide aggregation. Both render the solution unsuitable for research. Aggregation occurs when improperly stored peptides form insoluble complexes that no longer bind GHRH receptors. Particles may represent bacterial colonies or precipitated peptide fragments. Filter the solution through a 0.22-micron sterile filter if you need to confirm contamination versus aggregation, but in practice, any visible change from the clear colourless state warrants disposal.

SOURCE / realpeptides.co ↗
03What If I Accidentally Inject a Large Air Bubble Subcutaneously?+

You'll feel slight pressure or a small lump at the injection site that dissipates within 15–30 minutes as your body absorbs the air. There's no pain, no tissue damage, and no systemic effect. The injected peptide dose will be reduced by the bubble's volume. If you injected 0.2mL of air in a 0.5mL syringe, you received 0.3mL of CJC-1295 instead of the intended 0.5mL. The solution is to track this as an underdose and adjust your next injection timing or consult your research protocol to determine whether to compensate.

SOURCE / realpeptides.co ↗
04What If My Study Results Don't Match Published GH Response Curves?+

Request a certificate of analysis with HPLC chromatogram from your peptide supplier and compare the actual purity percentage to what was stated at purchase. If the supplier can't provide third-party sequence verification, assume contamination and redesign the study arm with verified peptide. A 10% purity variance translates to 10% lower effective dose. Which explains blunted GH responses that don't reach statistical significance.

SOURCE / realpeptides.co ↗
05What If IGF-1 Increases Less Than 20ng/mL After 8 Weeks on the Standard 50+ Protocol?+

Increase the GHRP dose to 250–300mcg per administration while keeping CJC-1295 at 200mcg twice weekly. If IGF-1 remains unchanged after another 4 weeks, the limitation is likely hepatic, not pituitary. Order a metabolic panel (fasting glucose, HbA1c, liver enzymes) and assess for insulin resistance or hepatic steatosis. Correcting the metabolic substrate through dietary intervention or metformin often restores IGF-1 responsiveness within 6 weeks. Increasing CJC-1295 dose beyond 200mcg twice-weekly in confirmed non-responders achieves nothing except higher peptide waste.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

Metabolic and Anti-Aging Research

The age-related decline in GH secretion, termed somatopause, has prompted investigation of GH secretagogues including CJC-1295 for potential anti-aging applications. Research protocols evaluate effects on body composition, bone density, cardiovascular function, cognitive performance, and quality of life in aging populations. Preliminary data suggest improvements in lean body mass, reduced visceral adiposity, enhanced exercise capacity, and improved markers of metabolic health. However, long-term randomized controlled trials are necessary to establish efficacy, optimal dosing, and safety in these applications. Additional research areas include investigation of CJC-1295 in HIV-associated lipodystrophy, cachexia syndromes, critical illness, and recovery from traumatic injury—contexts where anabolic stimulation may provide therapeutic benefit. The peptide's effects on wound healing and tissue repair show mechanistic overlap with other regenerative peptides such as TB-500 and BPC-157, suggesting potential for combination approaches in these applications https://pubmed.ncbi.nlm.nih.gov/19401417/.

RESEARCH

CJC-1295 for Growth Hormone Release: Research Combinations and Protocols

One of the most studied approaches in GH secretagogue research involves pairing CJC-1295 with a ghrelin receptor agonist. Ghrelin mimetics like Ipamorelin act on a completely separate receptor pathway (the GHS-R1a receptor), and when combined with a GHRH analog, the two signals work synergistically to amplify GH output beyond what either compound achieves alone. "Combining a GHRH analog with a ghrelin mimetic targets two independent receptor pathways simultaneously, producing a more robust GH pulse than either agent alone." This synergistic approach is explored in detail within the CJC-1295 plus Ipamorelin research overview, which outlines how these two peptide classes complement each other in research models. Multi-peptide blend research has also expanded. Formulations that include Tesamorelin, CJC-1295, and Ipamorelin represent a growing area of interest for researchers studying combined GH axis stimulation. Similarly, researchers reviewing Sermorelin, Ipamorelin, and CJC-1295 combinations have examined how stacking multiple GHRH-related peptides affects overall GH axis response.

POTENTIAL BENEFITS

What Are the Benefits of CJC 1295 Treatment in Arizona?

CJC 1295 treatment offers a plethora of benefits, making it a popular choice for those looking to optimize their health and well-being. Here are some of the key advantages:
05

Product & matchup locker

Linked catalog and comparison files.

Comparison

CJC-1295 vs Ipamorelin: Protocol Comparison for 20s

Many protocols pair CJC-1295 with ipamorelin, a ghrelin mimetic that stimulates GH release through a different receptor pathway (GHS-R1a rather than GHRH-R). The rationale: dual-p…

Comparison

Peptide Stability Factors: A Comparison

Here's a quick overview of critical factors affecting peptide stability, especially relevant to understanding CJC-1295 degradation reconstituted: pH of Solvent Extreme acidic/alka…

Continue reading

Related articles